470478-90-1

Basic information

• Product Name: 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER
• Synonyms: TERT-BUTYL 4-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL]TETRAHYDRO-1(2H)-PYRAZINECARBOXYLATE;4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER;4-[4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL]PHENYLBORONIC ACID PINACOL ESTER;4(N-TERT-BUTOXYCARBONYLPIPERAZINE)BENZENEBORONIC ACID PINACOL ESTER;4-Piperazin-1-ylbenzeneboronic acid pinacol ester, N4-BOC protected;Tert-butyl4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)tetrahydro-1(2H)-pyrazinecarboxylate;4-[4-(N-Boc)piperazin-1-yl]phenylboronic acid pinacol ester;t-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazinecarboxylate
• CAS NO: 470478-90-1
• Molecular Formula: C₂₁H₃₃BN₂O₄
• Molecular Weight: 388.31
• Product Categories: Aryl;Boronic ester;Organoborons
• Mol File: 470478-90-1.mol

Chemical Properties

• Melting Point: 157 °C
• Boiling Point: 501.7 °C at 760 mmHg
• Flash Point: 257.2 °C
• Appearance: /
• Density: 1.11
• Vapor Pressure: 3.4E-10mmHg at 25°C
• Refractive Index: 1.536
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 3.06±0.10(Predicted)
• CAS DataBase Reference: 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER(470478-90-1)
• EPA Substance Registry System: 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER(470478-90-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 470478-90-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER is used as a reactant for the preparation of 211Atand 125I-radiolabeled compounds. These radiolabeled compounds are crucial in the development of targeted radiopharmaceuticals for diagnostic and therapeutic applications in nuclear medicine. 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER's ability to form stable boronate esters allows for the efficient incorporation of radioactive isotopes, enhancing the effectiveness of these radiopharmaceuticals in detecting and treating various diseases, including cancer.
Used in Radiochemistry Research:
In the field of radiochemistry, 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER is used as a valuable building block for the synthesis of novel radiotracers. These radiotracers are essential tools in understanding biological processes and developing new therapeutic strategies. 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER's unique chemical properties enable the design and synthesis of innovative radiotracers with improved targeting and imaging capabilities.
Used in Cancer Research:
4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER plays a significant role in cancer research, particularly in the development of targeted alpha therapy (TAT) agents. These agents utilize alpha-emitting radionuclides, such as 211At, to deliver highly cytotoxic radiation directly to cancer cells, minimizing damage to surrounding healthy tissue. 4-(4-TERT-BUTOXYCARBONYLPIPERAZINYL)PHENYLBORONIC ACID, PINACOL ESTER's ability to form stable boronate esters with radionuclides makes it an essential component in the design and synthesis of TAT agents.

InChI:InChI=1/C21H33BN2O4/c1-19(2,3)26-18(25)24-14-12-23(13-15-24)17-10-8-16(9-11-17)22-27-20(4,5)21(6,7)28-22/h8-11H,12-15H2,1-7H3

Upstream product

• 106-37-6 1.4-dibromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 589-87-7 1,4-bromoiodobenzene 
• 104-95-0 (4-bromophenyl)thioanisole 
• 909418-89-9 tert-butyl 4-(4-(methylthio)phenyl)piperazine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 
• 66698-28-0 1-(4-bromophenyl)piperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 352437-09-3 tert-butyl 4-(4-bromophenyl)piperazine-1-carboxylate 
• 374930-88-8 tert-butyl 4-(5-bromopyrimidin-2-yl)piperazine-1-carboxylate 

Downstream Products

• 1388142-58-2 {4-[4'-(5-chloro-1H-benzimidazol-2-yl)biphenyl-4-yl]piperazin-1-yl}acetic acid 
• 1388144-39-5 5-chloro-2-(4'-piperazin-1-ylbiphenyl-4-yl)-1H-benzoimidazole 
• 1388144-38-4 4-[4'-(5-chloro-1H-benzoimidazol-2-yl)biphenyl-4-yl]piperazine-1-carboxylic acid tert-butyl ester 
• 1379522-35-6 tert-butyl 4-(4-{[4-(methylsulfonyl)benzyl]oxy}phenyl)piperazine-1-carboxylate 
• 158985-25-2 tert-butyl 4-(4-hydroxyphenyl)piperazine-1-carboxylate 
• 1415794-62-5 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperazine hydrochloride salt 
• 1571828-44-8 5-(4-(piperazin-1-yl)phenyl)indan-1-one 
• 1571828-45-9 C₂₂H₂₀N₄ 
• 1571828-28-8 tert-butyl 4-(4-(1-(dicyanomethylene)-2,3-dihydro-1H-inden-5-yl)phenyl)piperazine-1-carboxylate 
• 1571828-18-6 tert-butyl 4-(4-(1-oxoindan-5-yl)phenyl)piperazine-1-carboxylate 

Relevant articles and documents

Nucleophilic18F-Labeling of Spirocyclic Iodonium Ylide or Boronic Pinacol Ester Precursors: Advantages and Disadvantages

The field of labeling electron-rich aryl compounds with nucleophilic [18F]fluoride has recently expanded with radiofluorination strategies that apply boronic esters or spirocyclic iodonium ylides as precursors. Herein, we present a direct compa

POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Small molecule compounds

The invention provides small molecule compounds. The compounds are characterized in that the small molecule compounds are compounds represented by a structural formula shown in the specification or stereoisomers, geometric isomers, tautomers, racemates, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compounds. The small molecule compounds provided by the invention can be used as efficient and specific JAK kinase inhibitors, especially Tyk2 inhibitors, and/or JAK1 inhibitors, and/or JAK1/Tyk2 dual inhibitors.

Substituted piperazine compounds and method and use thereof

The invention relates to a new piperazine compound and a drug composition comprising the compound, which are used for inhibiting 5-hydroxytryptamine reuptake and/or agonizing 5-HT1A receptors. The invention also relates to methods for preparing the compou

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES

The present disclosure relates to bifunctional compounds, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A-RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

METALLOENZYME INHIBITOR COMPOUNDS

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Rhodium-Catalyzed ipso-Borylation of Alkylthioarenes via C-S Bond Cleavage

Rhodium-catalyzed transformation of alkyl aryl sulfides into arylboronic acid pinacol esters via C-S bond cleavage is reported. In combination with transition-metal-catalyzed sulfanyl group-guided regioselective C-H borylation reactions of alkylthioarenes, this method allows the synthesis of a diverse range of multisubstituted arenes.

HETEROCYCLIC COMPOUND

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.